

Ref: Syn/CS/SE/IP/Nov 2017

Syngene

Syngene International Limited
Biocon Park SEZ, Bommasandra IV Phase,
Jigani Link Road, Bangalore 560 099,
India.
T +91 80 2808 2808
F +91 80 4014 3150 / 2852 3423
CIN No. L85110KA1993PLC014937
www.syngeneintl.com

November 3, 2017

To, The Manager Listing The BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268	To, The Manager Listing The National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
---	---

Dear Sir/Madam,

Subject: Investor Presentation under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

This has reference to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the Investor Presentation for the quarter and half year ended September 30, 2017. The company will use this presentation for any meeting scheduled with analysts or institutional investors up to December 31, 2017.

The above mentioned Investor Presentation will also be available on website of the Company www.syngeneintl.com.

Request you to take the same on record.

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**



Mayank Verma

Company Secretary

E: Mayank.verma@syngeneintl.com

T: + 91 80 6775 8781/82/83



Syngene

Putting Science to Work

Investor Presentation

October 2017

Quality
Innovation
Confidentiality
Science



Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.



Putting Science to Work

Introduction

The Biocon Group


- Services Based
- Contract Discovery
- Contract Development
- Contract Manufacturing

Syngene

Biocon

- Product Based
- Biosimilars
- Formulations and Compounds
- Alternative Therapeutic Drugs

Syngene's Shareholding Pattern¹





- Established in 1994 as India's first Contract Research Organization – 23 years of unparalleled experience in novel molecule discovery & development services
- Integrated service platform for small & large molecules, antibody-drug conjugates and oligonucleotides
- World class infrastructure audited successfully by US FDA, EMA, AAALAC and major life sciences partners
- 293* global clients across industries ranging from pharma, biotech, nutrition, agrochemicals, animal health, specialty chemicals, consumer goods, academic and nonprofit organizations
- 1.3 Mn sq. ft. world-class R&D & manufacturing infrastructure; ~3500 professional workforce including ~3100 qualified scientists*

Quarter Highlights:

- Growth picks up in Q2FY18 on the back of growth in Chemical Development and Dedicated R&D Center Verticals.
- Sustained profitability margins at historical levels with EBITDA growing from Rs. 1,219 Mn in Q2 FY17 to Rs. 1,299 Mn in Q2 FY18. PAT has grown from Rs. 747 Mn in Q2 FY17 to Rs. 769 Mn in Q2 FY18.
- Strengthened our Bio equivalence study capabilities by setting up an additional 76-bed Human Pharmacology Unit (HPU) in Bangalore.
- The company also incorporated a wholly owned overseas subsidiary in the USA; Syngene USA Inc. which will provide a strong local footprint in the US market and will allow North America clients easy and local access to business teams..

All figures in INR Mn unless otherwise specified

P&L Summary	Q2 FY18	Q2 FY17	YoY Change
Revenue	3,516	3,193	10%
EBITDA	1,299	1,219	7%
<i>EBITDA Margin</i>	37%	38%	
PAT	769	747	3%
<i>PAT Margin</i>	22%	23%	

P&L Summary	H1 FY18	H1 FY17	YoY Change
Revenue	6,599	6,097	8%
EBITDA	2,431	2,266	7%
<i>EBITDA Margin</i>	37%	37%	
PAT	1,389	1,345	3%
<i>PAT Margin</i>	21%	22%	

Journey Over the Years



2002

20,000 sq. ft facility

100+

- Chemistry
- Preliminary biology

\$5 million



1.3 million sq. ft facility

~3,500

- End-to-End discovery, development and manufacturing capabilities

\$225 million

2017*

One of the leading India-based CROs

Integrated discovery and development platform

Focus on novel molecular entities


293⁽¹⁾ clients across multiple sectors

96%⁽¹⁾ of revenues from outside India

3,053⁽¹⁾ qualified scientists

World-class R&D and manufacturing infrastructure spread over 1.3⁽¹⁾ Million sq. ft facility.

Strong Growth and Profitability



Who we are and what we do

- Combining world class research talent and infrastructure with the Indian cost advantage
- Converting R&D to a variable cost for clients
- Moving beyond cost arbitrage to R&D productivity and innovation

Key Differentiators of Growth



Scalable



Predictable



De-risked



Profitable






Putting Science to Work


Our Industry

- **Large and growing addressable market**
 - Global R&D expenditure expected to increase from \$139bn in 2014 to \$152bn in 2018 (CAGR of 2.3%)
 - 75% of R&D spend can be potentially outsourced
- **Increasing per unit R&D cost for pharma**
 - 8x increase in cost per Novel Molecular Entity from \$140m in the mid-1970s to \$1,200m early-2000s
- **Increasing outsourcing penetration driven by:**
 - Focus on core competencies
 - Emergence of “virtual” companies
 - Shift from fixed to variable cost models




Outsourcing Market by Stage of DD Continuum

(USD bn)



Significant Growth in APAC

Global NME Discovery Outsourcing Market (USD bn)







Putting Science to Work

Business Overview


The Drug Discovery Continuum




Syngene offers an **Integrated Service Platform** for both small and large molecules



Wide Spectrum of Services Across a Range of Molecules Including Antibody-Drug Conjugates and Oligonucleotides



Entry points create opportunity for customer engagement expansion

Customer Focus**Cost Arbitrage****R&D Productivity****Innovation**



Dedicated centers

- Integrated Services
- Dedicated Infrastructure customized for client's requirements
- Long term, FTE based contracts
- Currently 5 in place: BBRC, ANRD, BGRC SARC and Herbalife Nutrition Research Centre



Discovery Services

- Discovery Chemistry, Discovery Biology and in-vivo services
- Multi-client infrastructure
- Largely FTE based engagements, typically renewed annually
- High renewal rates



Development & Manufacturing Services

- Preclinical studies, Stability, formulation, CMC and Clinical supplies, Clinical development etc.
- Largely FFS based services (both short and long term)
- High renewal rates in Manufacturing services



Bristol-Myers Squibb

Largest R&D Centre in Asia for BMS (2009). Contract extended till 2020.

Dedicated centre of research excellence with world class facilities.

Over 400 scientists supporting Novel Molecule research in small and large molecules.

Produced nine drug candidates for further study and advanced new compounds for first-in-human studies.



Dedicated research centre in India for Baxter (2013).

State of the art facility supporting R&D of medical products and devices worldwide.

Engages a multidisciplinary team of ~150 scientists.

R&D activities centered on product and analytical development, preclinical evaluation in parenteral nutrition and renal therapy.



Abbott Nutrition's 1st R&D centre in India set up in collaboration with Syngene (2012). Contract extended till December 2017.

Dedicated research centre supporting development of affordable, nutrition products.

~30 multi-disciplinary scientists engaged in product development lifecycle.

Focus on maternal, pediatric, neo-natal nutrition and diabetes care in line with emerging market needs.



Exclusive R&D Centre for Amgen Inc. in India (2016).

State-of-the-art dedicated centre supporting variety of discovery & development projects for biotechnology and small molecule medicines.

Engages a multidisciplinary team of ~ 100 scientists. Contract expanded for 185 scientist.

Focus on medicinal & process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research and pharmaceutical development.




HERBALIFE
Independent Distributor

Herbalife first Nutrition Research and Development Lab India at Syngene's Campus (2016).

Dedicated centre spans at 3,000 Sq.ft. and houses cGMP formulation lab to support product testing, sampling and end-product development.


Focus on product development, sensory evaluation and testing, scientific content writing, project management, formulation development, analytical service, stability study and other related services.






- Encompass activities across multiple disciplines as a molecule moves from pre-clinical to clinical trials
- Key activities include:
 - *Drug substance development (process R&D and optimization)*
 - *Drug product development (pre-formulation and formulation development)*
 - *Allied services (stability services, viral testing, bioanalytical)*
- Primarily FFS engagements which increase in volume/scale over time

Small Molecules



- A State-of-the-art cGMP facility to Manufacture NCEs
- Designed to support multi gram to 100s of kgs/ batch of Intermediates, & APIs for Clinical Trials; Current capacity can support initial commercial supplies
- New greenfield investment being made in Mangalore to support larger commercial scale requirements

Large Molecules



- Mammalian and microbial capabilities
- Can support early stage supply requirements (toxicology, preclinical, phase 1 & II a)
- Capacities being expanded at Bangalore to support large volumes for late stage clinical requirements



Multiple Layers of Growth

Expand/Extend existing clients


- High service integration
- Dedicated centres model

Engage New Clients

- Tailored service offerings and dedicated personnel

Moving from CRO to CRAMS with commercial manufacturing

- “Follow the molecule” by expanding into commercialisation



Capacity Expansion

- Consistent expansion
- FTE services, manufacturing, formulation, biologics, stability

Capability Additions

- New capabilities across multiple domains incl. the allied sectors
- Stability, analytical & bio-analytical services, viral testing, Oligonucleotide bioinformatics
- New platforms: siRNA, ADC

Investment of upto \$200 Mn in expansion of our facilities over FY16 to FY19



Putting Science to Work

Financial Highlights

Q2 & H1 FY18 Financial Highlights

All figures in INR Mn unless otherwise specified

Particulars	Q2 FY18	Q2 FY17	YoY Change	H1 FY18	H1 FY17	YoY Change
Revenue	3,516	3,193	10%	6,599	6,097	8%
Material & Power costs	879	869	1%	1,667	1,663	0.2%
Employee costs	937	767	22%	1,797	1,506	19%
Gross Margin	1,700	1,557	9%	3,135	2,928	7%
Gross Margin (%)	48%	49%		48%	48%	
Other Expenses	401	338	19%	704	662	6%
EBITDA	1,299	1,219	7%	2,431	2,266	7%
EBITDA Margin (%)	37%	38%		37%	37%	
Depreciation, Interest & tax	530	472	12%	1,042	921	13%
Profit After Tax	769	747	3%	1,389	1,345	3%
PAT Margin (%)	22%	23%		21%	22%	

All figures in INR Mn unless otherwise specified


Particulars	FY17	FY16	YoY Change
Revenue	12,716	11,133	14%
Material & Power costs	3,522	3,412	3%
Employee costs	3,086	2,493	24%
Gross Margin	6,108	5,228	17%
Gross Margin (%)	48%	47%	
Other Expenses	1,325	1,361	(3%)
EBITDA	4,783	3,867	24%
EBITDA Margin (%)	38%	35%	
Depreciation, Interest & tax	1,910	1,459	31%
Profit After Tax	2,873	2,408	19%
PAT Margin (%)	23%	22%	

Balance Sheet Highlights

As on 31st March 2017


Shareholders' funds	14,131
Net Fixed assets	9,853
Other net assets ⁽¹⁾	1,928
Net cash/(debt) ⁽²⁾	2,350
Total Use of Funds	14,131

- Growth driven by increase in sales from existing clients and acquisition of new clients
- “Engage, expand and extend” strategy to extend client relationship over a longer period of time
 - Growth in total number of clients
 - Increase in average revenue from largest clients
 - Increase in number of services offered to clients




All figures in INR Mn unless otherwise specified


Operating Margin (EBITDA)




Profit After Tax Margin (Net Income)



Historical Capital Investments – Average Gross Block (INR Mn)



Gross Block Turnover Ratio⁽¹⁾



- Capex towards capacity expansions, capability additions and technology up-gradations
- Key facility additions during the last three years include dedicated facility for Abbott, Baxter, Amgen, Herbalife and new formulation facility

Planned Capital Expenditure

- Expansion Capex of US\$200 million envisaged over FY16 to FY19
- Future funding requirements to be met through internal accruals & debt

Capex investment area

- Research centre
- Formulation centre

Late stage & commercial manufacturing

- Expansion of API plant
- Commercial NCE manufacturing plant
- Biologics manufacturing plant

Other services & new capabilities

- Oligonucleotides
- Viral testing services
- ADCs
- Bioinformatics

Risk	Mitigation
Client growth and sustained retention	<i>Proactive client engagement and sustained quality</i>
Currency fluctuation (USD/INR)	<i>Comprehensive hedging policy and tracking mechanism in place</i>
Significant capex investment over next few years	<i>Staggered investments in line with business visibility</i>
Sustainability of margin profile	<i>Strong cost control systems, productivity improvement initiatives</i>

THANK YOU

www.syngeneintl.com

For more details

- Visit www.syngeneintl.com
- IR Contact :
Chanderlekha Nayar
+91 80 6775 8821
+91 725 919 2001
chanderlekha.nayar@syngeneintl.com